849217-68-1 | N'-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide

97-67-6    849217-68-1    1140909-48-3 

[1]Patent:CN105503717,2016,A,.Locationinpatent:Paragraph0050

[2]Patent:WO2010/83414,2010,A1,.Locationinpatent:Page/Pagecolumn26-27

[3]Patent:WO2012/109510,2012,A1,.Locationinpatent:Page/Pagecolumn31

[4]Patent:WO2013/59788,2013,A1,.Locationinpatent:Paragraph0070;0071;0072

[5]Patent:WO2013/43840,2013,A1,.Locationinpatent:Paragraph00119;00131

[6]Patent:WO2013/166296,2013,A1,.Locationinpatent:Paragraph00125

[7]Patent:WO2014/165786,2014,A1,.Locationinpatent:Paragraph00206

[8]Patent:WO2015/164869,2015,A1,.Locationinpatent:Paragraph00263;00275

[9]Patent:WO2015/177758,2015,A1,.Locationinpatent:Page/Pagecolumn18;19

[10]Patent:WO2016/22697,2016,A1,.Locationinpatent:Paragraph00111;00123

[11]Patent:US2016/772,2016,A1,.Locationinpatent:Paragraph0095;0101

[12]Patent:TWI516477,2016,B,.Locationinpatent:Page/Pagecolumn31;35;36

849217-54-5    849217-60-3    849217-68-1 

[1]Patent:CN106632028,2017,A.Locationinpatent:Paragraph0079;0086;0087

[2]Patent:WO2005/30140,2005,A2.Locationinpatent:Page/Pagecolumn212

190728-25-7   

1-(4-fluorophenyl)carbamoylcyclopropane-1-carbonylchloride 

  849217-68-1 

[1]Patent:WO2010/83414,2010,A1.Locationinpatent:Page/Pagecolumn26

[2]Patent:US2012/70368,2012,A1

[3]Patent:WO2012/109510,2012,A1.Locationinpatent:Page/Pagecolumn30

[4]Patent:US2012/252840,2012,A1

[5]Patent:WO2013/59788,2013,A1.Locationinpatent:Paragraph0066;0067;0068

[6]Patent:WO2013/43840,2013,A1.Locationinpatent:Paragraph00111;00117

[7]Patent:WO2013/70890,2013,A1.Locationinpatent:Paragraph00124-00125

[8]Patent:WO2013/166296,2013,A1.Locationinpatent:Paragraph00121

[9]Patent:WO2014/165786,2014,A1.Locationinpatent:Paragraph00202

[10]Patent:WO2014/165779,2014,A1.Locationinpatent:Paragraph0077;0078;0085;0086;0087;0088

[11]Patent:WO2015/164869,2015,A1.Locationinpatent:Paragraph00255;00261

[12]Patent:WO2016/22697,2016,A1.Locationinpatent:Paragraph00111;00119

[13]Patent:US2016/772,2016,A1.Locationinpatent:Paragraph0095;0100

[14]Patent:TWI516477,2016,B.Locationinpatent:Page/Pagecolumn31;35

[15]Patent:EP2758057,2017,B1.Locationinpatent:Paragraph0112

[16]Patent:CN103664778,2017,B.Locationinpatent:Paragraph0054;0056;0067;0068

[17]Patent:WO2018/136796,2018,A1.Locationinpatent:Paragraph0081;0082;0094;0095;0096;0097;0098;0099

[18]Patent:CN104370811,2019,B.Locationinpatent:Paragraph0086-0089

[19]Patent:WO2018/227119,2018,A1.Locationinpatent:Paragraph00163;00176-00177;00178-00181

[20]OrganicPreparationsandProceduresInternational,2019,vol.51,p.381-387

[21]Patent:US2020/255382,2020,A1.Locationinpatent:Paragraph0111;0117;0119;0127-0130

97-67-6    849217-68-1    1140909-48-3 

[1]Patent:CN109836382,2019,A.Locationinpatent:Paragraph0088-0091

[2]Patent:CN105503717,2016,A.Locationinpatent:Paragraph0050

[3]Patent:WO2010/83414,2010,A1.Locationinpatent:Page/Pagecolumn26-27

[4]Patent:WO2012/109510,2012,A1.Locationinpatent:Page/Pagecolumn31

[5]Patent:WO2013/59788,2013,A1.Locationinpatent:Paragraph0070;0071;0072

[6]Patent:WO2013/43840,2013,A1.Locationinpatent:Paragraph00119;00131

[7]Patent:WO2013/166296,2013,A1.Locationinpatent:Paragraph00125

[8]Patent:WO2014/165786,2014,A1.Locationinpatent:Paragraph00206

[9]Patent:WO2015/164869,2015,A1.Locationinpatent:Paragraph00263;00275

[10]Patent:WO2015/177758,2015,A1.Locationinpatent:Page/Pagecolumn18;19

[11]Patent:WO2016/22697,2016,A1.Locationinpatent:Paragraph00111;00123

[12]Patent:US2016/772,2016,A1.Locationinpatent:Paragraph0095;0101

[13]Patent:TWI516477,2016,B.Locationinpatent:Page/Pagecolumn31;35;36

[14]Patent:WO2018/227119,2018,A1.Locationinpatent:Paragraph00163;00164;00182-00183;00184-00185

[15]Patent:CN104649969,2019,B.Locationinpatent:Paragraph0091-0098

617-48-1    849217-68-1   

N-(4-6,7-bis(methoxy)quinolin-4-yloxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamidemalate 

[1]Patent:WO2010/83414,2010,A1.Locationinpatent:Page/Pagecolumn29

371-40-4    849217-68-1 

[1]Patent:US2012/70368,2012,A1

[2]Patent:WO2012/109510,2012,A1

[3]Patent:WO2013/59788,2013,A1

[4]Patent:WO2013/43840,2013,A1

[5]Patent:WO2013/70890,2013,A1

[6]Patent:WO2013/166296,2013,A1

[7]Patent:WO2014/165786,2014,A1

[8]Patent:WO2014/165779,2014,A1

[9]Patent:WO2015/164869,2015,A1

[10]Patent:WO2016/22697,2016,A1

[11]Patent:US2016/772,2016,A1

[12]Patent:TWI516477,2016,B

[13]Patent:EP2758057,2017,B1

[14]Patent:CN103664778,2017,B

[15]Patent:CN106632028,2017,A

[16]Patent:CN106632028,2017,A

[17]Patent:WO2005/30140,2005,A2

[18]Patent:WO2005/30140,2005,A2

[19]Patent:WO2018/227119,2018,A1

[20]Patent:WO2018/227119,2018,A1

[21]OrganicPreparationsandProceduresInternational,2019,vol.51,p.381-387

[22]ArchivderPharmazie,2019,vol.352

[23]Patent:CN109836382,2019,A

[24]Patent:CN110903240,2020,A

[25]Patent:US2020/255382,2020,A1

Title: Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.

Journal: Toxicology letters 20180701

Title: Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

Journal: Cancer discovery 20180701

Title: Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.

Journal: Expert review of clinical pharmacology 20160101

Title: Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Journal: The New England journal of medicine 20151105

Title: Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.

Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20140101

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters 20130801

Title: Novel molecular targeted therapies for refractory thyroid cancer.

Journal: Head & neck 20120501

Title: Novel molecular targets for the therapy of castration-resistant prostate cancer.

Journal: European urology 20120501

Title: Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.

Journal: Cancer discovery 20120301

Title: c-Met is a marker of pancreatic cancer stem cells and therapeutic target.

Journal: Gastroenterology 20111201

Title: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Journal: Molecular cancer therapeutics 20111201

Title: Novel therapies for metastatic castrate-resistant prostate cancer.

Journal: Journal of the National Cancer Institute 20111116

Title: Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).

Journal: Drugs of today (Barcelona, Spain : 1998) 20111101

Title: VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.

Journal: Cancer research 20110715

Title: Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701

Title: Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110615

Title: The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.

Journal: The Journal of clinical endocrinology and metabolism 20110601

Title: XL184 (cabozantinib) for medullary thyroid carcinoma.

Journal: Expert opinion on investigational drugs 20110301

Title: Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.

Journal: Endocrine journal 20110101

Title: Novel treatment of medullary thyroid cancer.

Journal: Current opinion in endocrinology, diabetes, and obesity 20091001